FY2024 Earnings Estimate for Alector Issued By William Blair

Alector, Inc. (NASDAQ:ALEC - Free Report) - Research analysts at William Blair raised their FY2024 earnings per share (EPS) estimates for shares of Alector in a report issued on Wednesday, November 6th. William Blair analyst M. Minter now expects that the company will earn ($1.88) per share for the year, up from their previous forecast of ($1.89). The consensus estimate for Alector's current full-year earnings is ($1.92) per share. William Blair also issued estimates for Alector's Q4 2024 earnings at ($0.65) EPS, Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.48) EPS and FY2025 earnings at ($1.92) EPS.

Alector (NASDAQ:ALEC - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.10. Alector had a negative net margin of 257.54% and a negative return on equity of 102.50%. The firm had revenue of $15.34 million during the quarter, compared to analyst estimates of $16.33 million.

Several other equities analysts have also recently commented on ALEC. Cantor Fitzgerald reiterated an "overweight" rating on shares of Alector in a research note on Tuesday, September 17th. HC Wainwright restated a "buy" rating and issued a $35.00 target price on shares of Alector in a report on Thursday. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $17.75.

Alector Stock Performance

NASDAQ ALEC traded up $0.31 during trading hours on Monday, reaching $6.06. The company's stock had a trading volume of 752,686 shares, compared to its average volume of 622,427. The company's 50-day moving average is $5.07 and its two-hundred day moving average is $5.12. The stock has a market cap of $593.47 million, a PE ratio of -3.56 and a beta of 0.66. Alector has a fifty-two week low of $3.66 and a fifty-two week high of $8.90.

Insider Buying and Selling

In other news, CEO Arnon Rosenthal sold 26,499 shares of the business's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $129,315.12. Following the completion of the sale, the chief executive officer now owns 1,948,746 shares of the company's stock, valued at approximately $9,509,880.48. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Sara Kenkare-Mitra sold 13,926 shares of the firm's stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $67,958.88. Following the sale, the insider now directly owns 291,715 shares in the company, valued at approximately $1,423,569.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Arnon Rosenthal sold 26,499 shares of the firm's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $129,315.12. Following the sale, the chief executive officer now directly owns 1,948,746 shares in the company, valued at approximately $9,509,880.48. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 47,722 shares of company stock valued at $232,883. 9.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Alector

Large investors have recently added to or reduced their stakes in the business. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Alector in the 1st quarter worth about $760,000. Vanguard Group Inc. boosted its holdings in Alector by 12.0% during the first quarter. Vanguard Group Inc. now owns 4,912,578 shares of the company's stock worth $29,574,000 after purchasing an additional 526,037 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Alector by 211.6% during the 1st quarter. Acadian Asset Management LLC now owns 444,647 shares of the company's stock worth $2,675,000 after buying an additional 301,936 shares in the last quarter. Cubist Systematic Strategies LLC increased its position in shares of Alector by 73.1% during the second quarter. Cubist Systematic Strategies LLC now owns 92,218 shares of the company's stock valued at $419,000 after acquiring an additional 38,947 shares during the last quarter. Finally, Swiss National Bank grew its stake in Alector by 6.5% in the 1st quarter. Swiss National Bank now owns 131,900 shares of the company's stock valued at $794,000 after purchasing an additional 8,000 shares during the period. Institutional investors and hedge funds own 85.83% of the company's stock.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.